Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

Ruiz, Sabina; Gil, Joan; Biagetti, Betina; Venegas, Eva; Cámara, Rosa; García-Centeno, Rogelio; Gálvez, M. Ángeles; Picó, Antonio; Maraver, Silvia; González, Inmaculada; Abellán, Pablo; Trincado, Pablo; Herrera, María Teresa; Olvera, Pilar; Xifra, Gemma; Bernabéu, Ignacio; Serra‐Soler, Guillermo; Azriel, Sharona; García, Lourdes; Carvalho, Davide; Jordá, Mireia; Valassi, Elena; Puig, Josep; Puig‐Domingo, Manel

doi:10.1111/cen.14946

Cited by 6 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The long-term benefits of pasireotide in this patient population have also been confirmed in a variety of clinical and real-world settings, where 39–59% of patients who had previously failed on a first-generation somatostatin analog achieved normal IGF-1 levels on pasireotide beyond 6 months of treatment. 25 − 29 …”

Section: Discussionmentioning

confidence: 99%

Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide

Baagar,

Sadiq,

Khan

et al. 2024

Qatar Medical Journal

View full text Add to dashboard Cite

Background: The somatostatin analog, pasireotide, is used for the treatment of acromegaly after the failure of surgery and/or first-line medical treatment. Case Presentation: A 48-year-old male reported that during a workup for obesity in his home country, hyperprolactinemia was diagnosed and a 3.5 × 3.5 cm pituitary macroadenoma was identified on pituitary MRI. He received cabergoline for 6 months; then he was lost to follow-up. He presented at our Endocrine clinic 2 years later for treatment of obesity (BMI 49.5 kg/m 2 ). Biochemical workup revealed that in addition to hyperprolactinemia (7,237 [normal: 85–323 mIU/L), he had acromegaly, evident by elevated insulin-like growth factor 1 (IGF-1) level (450 [normal: 88–210 µg/L]), and a positive growth hormone suppression test, secondary hypothyroidism, and secondary hypogonadism. Pituitary MRI showed that the adenoma encased parts of the left and right internal carotid arteries and encroached on the optic chiasm. Surgical excision was therefore not feasible. He was treated with cabergoline and later, long-acting release (LAR) octreotide. Prolactin levels were reduced with cabergoline, but IGF-1 levels did not respond to octreotide, and it was discontinued. The patient abandoned radiotherapy after two sessions. He was started on LAR pasireotide 40 mg every 4 weeks and continued on cabergoline 0.5 mg per week. His biochemical response was dramatic, with a near normalization of IGF-1 levels in 3 months. After 6 months from starting pasireotide, we increased cabergoline dose from 0.5 mg/week to 3 mg/week. Three months later, IGF-1 level was normalized. The patient developed type 2 diabetes as a side effect of pasireotide; however, this was well-controlled with medications. Conclusions: The case suggests that pasireotide can provide marked biochemical improvement in acromegaly after the failure of both cabergoline monotherapy and cabergoline plus octreotide. This further confirms a potentially efficacious treatment regimen in treatment-resistant acromegaly with hyperprolactinemia.

show abstract

Section: Discussionmentioning

confidence: 99%